Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6675892 | 0.77 | CHRM2 (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2354299 | 0.72 | MLYCD (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5136628 | 0.71 | FAAH (0.41) | — | |
| SCHEMBL20421304 | 0.70 | MLYCD (0.31) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4439111 | 0.69 | FAAH (0.44) | — | |
| SCHEMBL3618071 | 0.69 | CHRM2 (0.31) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1063804 | 0.68 | — | — | |
| SCHEMBL3643142 | 0.67 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL28198385 | 0.67 | — | — | |
| SCHEMBL444539 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4280891-A1 | METHODS OF SELECTIVELY PROMOTING GASTROINTESTINAL MICROBIAL GROWTH | DSM IP Assets B.V. (NL) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023214405-A1 | REEXPRESSION OF HNF4A TO ALLEVIATE CANCER-ASSOCIATED CACHEXIA | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023077166-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-4118090-A1 | METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES | DSM IP Assets B.V. (NL) | 2023-01-18 | — | — | EP | disclosed |
| EP-4022293-A1 | OPTIMIZED ANALYTE DERIVATIZATION FOR SYNERGISTIC APPLICATION WITH CRYSTAL SPONGE METHOD | Merck Patent GmbH (DE) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021183896-A1 | METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES | DSM IP ASSETS, B.V. (NL) | 2021-09-16 | — | — | WO | disclosed |
| EP-3876747-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP Assets B.V. (NL) | 2021-09-15 | — | — | EP | disclosed |
| WO-2021037937-A1 | OPTIMIZED ANALYTE DERIVATIZATION FOR SYNERGISTIC APPLICATION WITH CRYSTAL SPONGE METHOD | MERCK PATENT GMBH (DE) | 2021-03-04 | — | — | WO | disclosed |
| EP-3551194-A1 | GLYCAN POLYMERS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3334437-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | Kaleido Biosciences, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3223834-A2 | PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND METHODS OF USE THEREOF FOR MODULATION OF THE MICROBIOME | Evelo Biosciences, Inc. (US) | 2017-10-04 | — | — | EP | disclosed |
| WO-2017035412-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2016172657-A2 | GLYCAN THERAPEUTICS AND METHODS OF TREATMENT | KALEIDO BIOSCIENCES, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| EP-3071235-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2016122889-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016086208-A1 | PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND METHODS OF USE THEREOF FOR TREATMENT AND PREVENTION OF GRAFT VERSUS HOST DISEASE | Epiva Biosciences, Inc. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016086209-A1 | PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND METHODS OF USE THEREOF FOR TREATMENT OF GASTROINTESTINAL DISORDERS | Epiva Biosciences, Inc. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016086205-A2 | PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND METHODS OF USE THEREOF FOR MODULATION OF THE MICROBIOME | Epiva Biosciences, Inc. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016086210-A1 | PROBIOTIC AND PREBIOTIC COMPOSTIONS, AND METHODS OF USE THEROF FOR TREATMENT AND PREVENTION OF GRAFT VERSUS HOST DISEASE | Epiva Biosciences, Inc. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20070203175-A1 | Productioin of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203175-A1 | Productioin of dolasetron | DDOST, ALG8, DUT | CHRM2 3870/4885CHRM4 3891/4885CHRM5 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.